Get started
Author

F. Skoulidis

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
2020 · T Cascone, WN William Jr., et al. · immuneACCESS · 41
LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study
2022 · M.L. Johnson, A.J. de Langen, et al. · Annals of Oncology · 39
PDF
Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients
2009 · V. Formica, M.C. Massara, et al. · Cancer Biomarkers · 27
PDF
Global advances and future directions in lung cancer care: expert consensus and strategic priorities
2026 · M.-L. Meyer, S. Peters, et al. · ESMO Open · 7
PDF
1012P Resistance mechanisms to dual EGFR and MET inhibition in patients with EGFR-mutant MET-amplified non-small cell lung cancer
2022 · K. Wang, R. Du, et al. · Annals of Oncology · 4
P3.18.65 Trial in Progress - RAsolve 301: A Phase 3 Study of Daraxonrasib (RMC-6236) Vs. Docetaxel in in Patients With Previously Treated RAS Mutant NSCLC
2025 · F. Skoulidis, K.C. Arbour, et al. · Journal of Thoracic Oncology · 2
P4.11D.01 TRITON: Tremelimumab + Durvalumab + Chemotherapy (CT) vs Pembrolizumab + CT in mNSCLC with STK11, KEAP1 and/or KRAS Mutations
2024 · F. Skoulidis, H. Borghaei, et al. · Journal of Thoracic Oncology · 2
PDF
MA10.05 Phase I/II Study of Nivolumab and Ipilimumab With Concurrent Stereotactic Radiosurgery for Intracranial Metastases From NSCLC
2025 · M. Altan, T. Beckham, et al. · Journal of Thoracic Oncology · 1
1305P Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials
2024 · F. Skoulidis, B.T. Li, et al. · Annals of Oncology · 1
EP08.02-163 Real-World Case Series on Efficacy and Safety of Amivantamab for EGFR-mutant Non-small Cell Lung Cancer
2022 · X. Le, R. Du, et al. · Journal of Thoracic Oncology · 1
P2.363: Rasolve 301: A Phase 3 Study of Daraxonrasib (RMC-6236) vs. Docetaxel in Patients With Previously Treated RAS-Mutant NSCLC
2026 · F. Skoulidis, K.C. Arbour, et al. · Journal of Thoracic Oncology
OA14.03: Clinical Outcomes of the Phase III Lonestar Trial: Local Consolidation Therapy After Nivolumab Plus Ipilimumab in NSCLC
2026 · M. Altan, S. Gandhi, et al. · Journal of Thoracic Oncology
156TiP RASolve 301: A phase III study of daraxonrasib (RMC-6236) vs. docetaxel in previously treated RAS-mutant non-small cell lung cancer (NSCLC)
2026 · H. Horinouchi, F. Skoulidis, et al. · ESMO Open
Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC
2026 · May-Lucie MEYER, Solange PETERS, et al. · Journal of Thoracic Oncology
PDF
D108-09 Selective Small Molecule Inhibitor of STAT3 Improves Immune Checkpoint Inhibitor Efficacy on Kras Mutant Lung Cancer by Reprogramming the Tumor Microenvironment
2026 · S Deng, N Karimi, et al. · American Journal of Respiratory and Critical Care Medicine
P1.11.70 Immune Cell Infiltration and Spatial Associations in the Tumor Microenvironment Following Dual ICI or ICI-Chemotherapy
2025 · M. Aminu, B. Zhu, et al. · Journal of Thoracic Oncology
PP01.10 A Randomized, Open-Label Phase 2 Study of the TORC 1/2 Inhibitor Sapanisertib in Relapsed/Refractory (R/R) NFE2L2 (NRF2)-Mutated and Wild-Type (WT) Squamous Non-Small Cell Lung Cancer (sqNSCLC)
2023 · J.W. Riess, M.L. Johnson, et al. · Journal of Thoracic Oncology
PDF
Évaluation de la résistance acquise au sotorasib dans le cancer colorectal (CCR) et le cancer bronchique non à petites cellules (CBNPC) avec mutation KRASG12C : analyse de biomarqueurs plasmatiques de l’étude CodeBreaK 100
2023 · J. Mazières, B.T. Li, et al. · Revue des Maladies Respiratoires Actualités
Works count: 16
Citation count: 125
H-index: 4
I10-index: 3
Year
Topic
Type